figshareBrowse
pone.0217964.g003.tif (1.05 MB)
Download file

Budgetary impact (shown in differential costs) of treating all diagnosed individuals compared to no treatment over various time horizons from 5–20 years and percentage diagnosed from 5 to 15% of the chronically infected population.

Download (1.05 MB)
figure
posted on 2019-06-06, 17:50 authored by Antoine Chaillon, Sanjay R. Mehta, Martin Hoenigl, Sunil S. Solomon, Peter Vickerman, Matthew Hickman, Britt Skaathun, Natasha K. Martin

Budgetary impact (shown in differential costs) of treating all diagnosed individuals compared to no treatment over various time horizons from 5–20 years and percentage diagnosed from 5 to 15% of the chronically infected population.

History

Usage metrics

Read the peer-reviewed publication

Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection
PLOS ONEPLOS ONE

Categories

Keywords

impact limit treatment scale-upHCV treatment scale-up planreinfection Background HCV direct-acting antiviralshealth care expenditureF 2-F individualsResults HCV treatmentConclusions HCV treatmentICERHCV disease progression0-FGDPhealth care payer perspectiveQALYUSDHCV treatmentDAAcohort Markov model

Licence

CC BY 4.0

Exports